My PCR
Create Account
Logo PCR

EuroPCR 2024 delivered an eye-opening focus on imaging guidance

A record 12,100 participants from 130 countries have just taken part in the highly educational WorldLeading Course in interventional cardiovascular medicine. They enjoyed a unique opportunity to exchange their knowledge, skills and experience on a global scale.

Paris – France, 17 May 2024. As always, the thought-provoking annual course was enhanced by a large amount of practical training and hands-on learning relevant to daily practice, while keeping the worldwide community up to date with the latest advancements in their fast-moving field. Imaging was an overarching theme for this edition of the official meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

In the Opening Ceremony the EuroPCR Course Directors promised a strong focus on imaging techniques, and it was evident throughout the programme. The hands-on Imaging Learning Centre sessions were particularly sought-after, where participants were eager to learn skills for bifurcation treatment guided by OCT, and to discover what imaging is needed prior to a TAVI procedure. Other sessions that triggered extremely keen interest were on topics such as side-branch management in provisional bifurcation stenting; how to set up the implementation of renal denervation in hypertension management; and the importance of commissural alignment in order to optimise TAVI.

During a dedicated session, enthusiastic participants heard renowned investigators share the muchanticipated results of three major late-breaking trials, expected to have a significant impact on current practice in cathlabs around the globe:

  • First TAVI vs. SAVR randomised trial in younger low-risk patients with severe tricuspid or bicuspid aortic valve stenosis - results from NOTION-2 - O. De Backer
  • One-month DAPT followed by 5-month Ti - cagrelor monotherapy in acute coronary syndromes with DCB - results from REC-CAGEFREE II- T. Ling
  • Early outcomes of a randomised non-inferiority trial comparing TAVI devices: the LANDMARK trial - P. W. Serruys

A number of ceremonies took place over the week, including a moving tribute to the recently departed Alain Cribier, an esteemed and much-appreciated pioneer in the non-invasive treatment of valvular disease. This year’s recipients of the Andreas Grüntzig Ethica Award were Ottavio Alfieri and Frederick St Goar, who developed new opportunities for expanding indications of intervention - targeting mitral regurgitation in patients with heart failure. The new Michele Pighi Young Investigator Award was given to Ryota Kakizaki, allowing him the opportunity to spend time working in the European interventional centre of his choice.

Other awards attributed over the week were:

  • Best Clinical Case - Mohammad Altermanini and Ana Vera Marinho
  • Best Scientific Abstract - Nader Mankerious
  • Best Clinical Case (NAP) - Ida Ellebaek Oland
  • Best Abstract (NAP) - Miryam Gonzalez Cebrian
  • PCR’s Got Talent - Christopher Rajkumar
  • Abbott award for the best personalised care project - Baiba Kokina

The EAPCI Annual General Assembly took place and included the handover of presidency from Emanuele Barbato to Alaide Chieffo. They also announced the results of their elections, with Martine Gilard being voted President Elect for the next two years.

PCR Innovators Day and EAPCI-PCR Fellows Course, celebrating 10 successful years, took place the day before EuroPCR. PCR Innovators Day gathered 450 participants to present and discuss the latest innovations, features, and projects, with a focus on valves, heart failure and renal denervation. Rishi Puri was rewarded with a generous grant of $200,000 by the Jon DeHaan Foundation, for the best innovation: “A-FLUX coronary sinus reducer for treating symptomatic ischemic heart disease”. The EAPCI-PCR Fellows Course brought together 200 early career participants, who engaged in extremely interactive case-based sessions on STEMI, left main, three-vessel disease and calcified stenosis, and gained precious tips on presentation skills.

The next edition of EuroPCR will take place on 20 – 23 May 2025, and in the meantime education and exchange will continue at several other PCR Courses:

NOTES TO EDITORS

About EuroPCR 2024

The World-Leading Course in interventional cardiovascular medicine and the official annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) took place from 14 to 17 May 2024, onsite at the Palais des Congrès, Paris, France. A digital package was also available for those unable to join in person.

About PCR

The mission of PCR is to serve the needs of each individual patient by helping the global cardiovascular community to share knowledge, experience and practice. PCR offers a large range of many other educational meetings and resources for the continuing education of the interventional cardiovascular community. These include major annual courses across the globe, e-learning with high-profile PCR Webinars, courses specifically dedicated to valvular heart disease, tailor-made PCR Seminars on specific topics, online resources and medical publications such as EuroIntervention, the official journal of the EAPCI.

Gateways to all PCR activities are available on www.pcronline.com
For further information, please contact Sally Collingridge: [email protected]

About the EAPCI

The European Association of Percutaneous Cardiovascular Interventions (EAPCI) is a branch of the European Society of Cardiology. Its mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions. This dynamic association represents a large community of over 8K EAPCI associates and over 1K full EAPCI members by helping them remain up to date in the constantly evolving field of PCI by publishing research and providing educational, training and certification programmes. The EAPCI also advocates for the best possible access to life saving treatments for patients through data-based advocacy at a European level.